-
Company Insights
Innovation and Patenting activity of AJU IB Investment Co., Ltd. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AJU IB Investment Co., Ltd. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Irritable Bowel Syndrome Drug Details: Psilocybin (TRP-8802) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Fibromyalgia (Fibromyalgia Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Fibromyalgia (Fibromyalgia Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Fibromyalgia (Fibromyalgia Syndrome) Drug Details: Psilocybin (TRP-8802) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CIN-103 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CIN-103 in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CIN-103 in Irritable Bowel Syndrome Drug Details: CIN-103 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naronapride in Corrosive Esophagitis (Erosive Esophagitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naronapride in Corrosive Esophagitis (Erosive Esophagitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naronapride in Corrosive Esophagitis (Erosive Esophagitis) Drug Details: Naronapride is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naronapride in Diabetic Gastroparesis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naronapride in Diabetic Gastroparesis Drug Details: Naronapride is under development for the treatment of multiple...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastroenteritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastroenteritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastroenteritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Dedifferentiated Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Pleomorphic Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Pleomorphic Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Pleomorphic Liposarcoma Drug Details: Pembrolizumab (Keytruda) is an antineoplastic...